BIIB’s Aduhelm: Medicare Coverage Proposal for Alzheimer’s Drugs

Nephron’s Sasha Simpson was out in front of clients this evening with an analysis of the just-released preliminary national coverage decision for BIIB’s Aduhelm and other amyloid-directed monoclonal antibodies used for treating Alzheimer’s disease.  The proposal would require Medicare beneficiaries to be enrolled in a randomized controlled clinical trial or NIH sponsored study as a condition of coverage.  Given the early reaction in the market, investors were caught a bit by surprise.  Broadly, the release was in line with our expectations with Sasha’s analysis focused on key elements of the proposal, impact and notably the outlook for a final decision and timing. Please email for more.